MAPT and dementia: Results from trials of symptomatic participants (i.e., those with MCI or mild dementia) suggest that amyloid clearance is more likely to be achieved in those who begin with lower amyloid levels(57) while other studies have shown that higher levels of amyloid PET burden are associated with longer presence of amyloid (e.g., (21)), greater preclinical cognitive decline (e.g., (20)), and more tau abnormalities (e.g., (58)).